Affiliation:
1. Associate Professor, Department of Biochemistry, Lokmanya Tilak Municipal Medical College & Hospital, Sion Mumbai.
2. Assistant Professor, Department of Biochemistry, Lokmanya Tilak Municipal Medical College & Hospital, Sion Mumbai.
3. Professor & Head, Department of Biochemistry, Lokmanya Tilak Municipal Medical College & Hospital, Sion Mumbai.
4. Ayurved Mahavidyalaya Sion, Mumbai.
Abstract
Introduction: Irritable Bowel Syndrome (IBS) is a group of intestinal symptoms which lasts at least three months for at
least three days per month. The symptoms of IBS typically include cramping, abdominal pain, bloating and gas,
constipation, diarrhoea. IBS also affects other organs like liver, kidney, pancreas also. BILVA is considered to have antioxidant, anti-
inammatory, immunomodulator, soothing and lubricating inuence on the body. In the present study, effect of Bilva on biochemical parameters
in patients of irritable bowel syndrome (IBS) have been studied. Biochemical evaluation of irritable bowel syndromeAim & Objectives:
patients before & after Bilva treatment. 30 diagnosed patients of irritable bowel syndrome were tested for biochemicalMaterial And Methods:
parameters including liver function test (LFT), renal function test (RFT), serum electrolytes, amylase, uric acid and minerals (Calcium,
phosphorus). All patients were treated with Bilva (Formulation prepared by ayurvedic medical college & hospital) at dosage of 3 gms BD for 2
months. Biochemical evaluation was repeated 15 days after the last dose of Bilva. Results obtained were statistically analysed by usingResults:
paired t test. Post treatment analysis of samples showed signicant (p<0.05) decrease in levels of Total bilirubin, ALT, BUN, uric acid, Creatinine,
& signicant (p>0.05) increase in levels of total protein, albumin, calcium, sodium, potassium & phosphorus. It can be concludedConclusion:
that BILVA treatment has benecial effect on the patients of irritable bowel syndrome & should be included as a routine treatment in management
of such patients.